NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, was pleased to welcome Congressman Robert C. "Bobby" Scott (D-Va) for an in-depth visit and tour of our Norfolk-based research and development facilities on July 24, 2023.
Congressman Scott, a long-standing advocate for healthcare innovation and economic development, took a keen interest in learning about the work done at ReAlta. During the visit, Congressman Scott toured ReAlta’s research laboratory, during which he observed first-hand the advanced research conducted by ReAlta scientists to develop innovative new EPICC peptides and translate research insights into new therapies for the clinic. The Congressman also met with members of ReAlta’s management team to discuss the company’s long-term growth strategies, ongoing clinical trials, and the potential impact of the company’s research on the lives of patients with acute inflammatory diseases such as hypoxic-ischemic encephalopathy, graft-versus-host disease, and acute pulmonary exacerbations.
"We were honored to host Congressman Scott and appreciated his interest in our work and the potential impact it could have on the health and well-being of our community and beyond," said Ulrich Thienel, MD, PhD, CEO of ReAlta Life Sciences. "These kinds of visits from our lawmakers not only affirm the significance of our scientific endeavors but also underline the importance of the biotech sector in our national economy and healthcare infrastructure."
“Thank you to Dr. Thienel and the entire team at ReAlta Life Sciences for hosting me for a tour and briefing,” said Congressman Bobby Scott. “Hampton Roads is home to many critical public and private assets advancing important scientific and medical research. I enjoyed learning more about ReAlta’s work and research to help patients facing life-threatening medical conditions.”
ReAlta is grateful to Congressman Scott for his visit and his ongoing support for biotechnology research and innovation in Virginia. The company looks forward to continuing to push the boundaries of what is possible in the fight against life-threatening rare diseases.
About ReAlta Life Sciences
ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to harnessing the power of the immune system to address life threatening rare diseases. The Company’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND clearance, and Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency, and Fast Track Designation for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018 and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.
